2012—2014年某院干部门诊口服降糖药应用分析

发布时间：2019-01-10 14:21

【摘要】：目的:对某院干部门诊口服降糖药的应用情况进行分析,提供临床合理用药的参考。方法:随机抽取2012—2014年某院干部门诊2型糖尿病患者处方2 108份,采用限定日剂量(DDD)法,对其使用的口服降糖药的药品种类、限定日费用(DDC)、用药频度(DDDs)、药物利用指数(DUI)、销售金额及其联合用药情况进行统计分析。结果:该院干部门诊口服降糖药销售金额逐年上升,阿卡波糖销售金额连续3年排在首位,二甲双胍、阿卡波糖、瑞格列奈DDDs值连续3年名列前三,除格列吡嗪(缓释)、瑞格列奈、罗格列酮外其余药物DUI值≤1。结论:该院干部门诊口服降糖药应用基本合理。
[Abstract]:Objective: to analyze the application of oral hypoglycemic drugs in a cadre outpatient clinic. Methods: a total of 2 108 prescriptions of type 2 diabetes mellitus patients were randomly selected from a cadre outpatient clinic in a certain hospital from 2012 to 2014. The drug types of oral hypoglycemic drugs used by them were determined by the method of limited daily dose (DDD), and the frequency of (DDC), drug use was limited by daily cost (DDDs),. Drug utilization index (DUI),) sales sum and its combined drug use were statistically analyzed. Results: the sales amount of oral hypoglycemic drugs increased year by year. The sales amount of acarbose was ranked first for 3 consecutive years. The DDDs value of metformin, acarbose and Regellinide ranked first for 3 consecutive years, except for glipizide (sustained release). The DUI of repaglinide and rosiglitazone were 鈮，

本文编号：2406414